Mark Cuban criticizes PBMs for higher U.S. drug prices
@mcuban: Mark Cuban criticizes PBMs
Mark Cuban has expressed concern over the difference in brand drug prices between the United States and other nations.
According to Cuban, the high prices of brand-name drugs in the U.S. can be attributed to the presence of Pharmacy Benefit Managers (PBMs), an industry unique to the nation. PBMs act as intermediaries between insurers, pharmacies, and manufacturers in the healthcare system, which has sparked debates over their influence on drug pricing.
Cuban's remarks on social media have ignited discussions about the role of PBMs in the U.S. healthcare industry. 'Want to know why those other countries have lower brand drugs prices than us? They do not have PBMs,' he stated. 'We are the ONLY country that uses PBMs. Insane.'
This viewpoint underscores ongoing concerns about the cost of healthcare and suggests a need for transparency in how drug pricing is determined in the U.S. In recent years, the growing influence of PBMs and their impact on drug prices have been subject to increasing scrutiny by consumers and lawmakers alike.
Loading...
Cuban's persistent scrutiny of Pharmacy Benefit Managers aligns with his prior assertions regarding how PBMs influence drug pricing in the healthcare sector. His ongoing critique, as detailed in his analysis of PBMs' role in corrupting the healthcare sector, continues to shape the debate over cost and transparency in the U.S. pharmaceutical industry.
